Windtree Therapeutics logo
WINTWindtree Therapeutics
Trade WINT now
Windtree Therapeutics primary media

About Windtree Therapeutics

Windtree Therapeutics (NASDAQ:WINT) is a biotechnology company focused on the development of therapeutics and diagnostics for the healthcare sector, particularly in the areas of acute pulmonary and cardiovascular diseases. Known for its passion for innovation, Windtree is advancing a broad range of projects aimed at addressing unmet medical needs. Among its key initiatives is the development of a unique surfactant therapy for acute respiratory conditions, as well as advancing its portfolio of early-stage programs targeting heart failure. The company’s objective is to transform the therapeutic landscape through the advancement of novel technologies and drugs that improve patient outcomes in critical care settings. Windtree Therapeutics is dedicated to pioneering new solutions that could potentially save lives and improve the quality of life for patients around the globe.

What is WINT known for?

Snapshot

Public US
Ownership
1992
Year founded
15
Employees
Warrington, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Produtos e/ou serviços de Windtree Therapeutics

  • Late-Stage Cardiovascular Interventions: Windtree prioritizes interventions for cardiovascular issues aimed at treating patients in critical moments.
  • Istaroxime (Lead Candidate): This is their most advanced product, designed as a first-in-class treatment for cardiogenic shock and acute heart failure. It has a dual mechanism of action to improve heart function.
  • SERCA2a Activators: This research program involves pre-clinical candidates targeting chronic heart failure, potentially for outpatients with heart failure with preserved ejection fraction (HfpEF).
  • Rofafuroxin: This is a novel drug candidate aimed at treating resistant hypertension in patients with specific genetic profiles.
  • Past Products (Out-licensed): Windtree previously developed and out-licensed Aerosurf and Surfaxin for respiratory distress syndrome in premature infants.
  • Future Pipeline: They might develop additional cardiovascular therapies based on their ongoing research and discoveries.

equipe executiva do Windtree Therapeutics

  • Mr. Jed A. LatkinCEO, President & Director
  • Mr. George CoxVice President of Technical Operations
  • Dr. Pratap ParuchuruExecutive Director of Clinical Development
  • Ms. Tracy RarickHead of Operations & Program Management

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.